Benchmark Reaffirms Buy Rating for Bio-Techne (NASDAQ:TECH)
Benchmark reaffirmed their buy rating on shares of Bio-Techne (NASDAQ:TECH – Free Report) in a report released on Thursday, Benzinga reports. The firm currently has a $95.00 target price on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada reduced their price objective on […]